

RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

Milan, 14 June 2013 – Following to the press releases dated 21 and 29 May and 6 June 2013 and always within the Recordati's share buy-back program announced on 9 May 2013 with the object of purchasing Recordati ordinary shares for the servicing of current and future stock option plans in favour of certain group employees, the Company informs the following purchase transactions, pursuant to art. 87 bis of Consob Regulation 11971/1999 ("Issuers Regulations").

SUMMARY OF TRANSACTIONS FROM 6 TO 13 JUNE 2013					
Date	Type of Transaction	Financial Instrument	Quantity	Average price	Consideration
06.06.2013	Purchase	Ord. Shares Recordati	30,000.00	8.0438	241,314.00
07.06.2013	Purchase	Ord. Shares Recordati	37,237.00	7.9088	294,499.99
11.06.2013	Purchase	Ord. Shares Recordati	65,000.00	8.0485	523,150.72
12.06.2013	Purchase	Ord. Shares Recordati	8,364.00	8.0446	67,285.03
13.06.2013	Purchase	Ord. Shares Recordati	3,004.00	8.0175	24,084.57
TOTAL			143,605.00		1,150,334.31

As at 13 June 2013, as part of the implementation of the above mentioned program, the Company purchased n. 763,881.00 own shares in Treasury stock for a total investment of € 6,131,838.47.

Between 6 and 13 June 2013 the Company has sold n. 170,000.00 in Treasury stock in favour of beneficiaries of Company's stock options plans in force, further to the exercise of options granted to them by these stock options plans. The sell price is equal to the exercise price fixed upon the granting of such options.

Therefore, in the light of the above on 13 June 2013, the Company has n. 7,423,421.00 own shares in Treasury stock which amount to 3.5497% of the current share capital.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 3,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey and in the United States of America. A field force of more than 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2012 was € 828.3 million, operating income was € 167.0 million and net income was € 118.5 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Media Relations

Ketchum

Cristina Risciotti, (39)0262411919, cristina.risciotti@ketchum.com

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832

e-mail: inver@recordati.it

Marzia Ongaretti, (39)0262411915, marzia.ongaretti@ketchum.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.